Comparing of MYOS RENS Technology Inc. (MYOS) and Mylan N.V. (NASDAQ:MYL)

Both MYOS RENS Technology Inc. (NASDAQ:MYOS) and Mylan N.V. (NASDAQ:MYL) compete on a level playing field in the Drugs – Generic industry. We will evaluate their performance with regards to profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MYOS RENS Technology Inc. N/A 36.35 4.24M -0.03 0.00
Mylan N.V. 11.59B 1.39 545.60M 1.24 24.47

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 has MYOS RENS Technology Inc. and Mylan N.V.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
MYOS RENS Technology Inc. 0.00% -117% -100%
Mylan N.V. 4.71% 4.3% 1.6%

Volatility & Risk

MYOS RENS Technology Inc. has a beta of 1.18 and its 18.00% more volatile than S&P 500. From a competition point of view, Mylan N.V. has a 1.52 beta which is 52.00% more volatile compared to S&P 500.


The current Quick Ratio of MYOS RENS Technology Inc. is 0.5 while its Current Ratio is 2. Meanwhile, Mylan N.V. has a Current Ratio of 1.3 while its Quick Ratio is 0.8. MYOS RENS Technology Inc. is better positioned to pay off its short-term and long-term debts than Mylan N.V.

Analyst Ratings

Ratings and Recommendations for MYOS RENS Technology Inc. and Mylan N.V. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
MYOS RENS Technology Inc. 0 0 0 0.00
Mylan N.V. 0 3 4 2.57

Meanwhile, Mylan N.V.’s average target price is $41.4, while its potential upside is 32.48%.

Institutional and Insider Ownership

The shares of both MYOS RENS Technology Inc. and Mylan N.V. are owned by institutional investors at 1.6% and 87.2% respectively. Insiders held roughly 42.92% of MYOS RENS Technology Inc.’s shares. Competitively, 5.68% are Mylan N.V.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
MYOS RENS Technology Inc. -1.8% -14.84% -19.86% -33.54% -18.05% -19.64%
Mylan N.V. -10.51% -17.1% -20.24% -27.46% -18.92% -28.39%

For the past year MYOS RENS Technology Inc. has stronger performance than Mylan N.V.


Mylan N.V. beats on 8 of the 11 factors MYOS RENS Technology Inc.

MYOS RENS Technology Inc., a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity. Its products include Re Muscle Health products, a direct-to-consumer portfolio of muscle health bars, meal replacement shakes, and daily supplement powders; and Qurr line of products comprising flavored puddings, powders, and shakes. The company sells its Re Muscle Health products through e-commerce Websites; and Qurr line of products through convenient direct online ordering without a prescription. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; antiretroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures; and Dymista, which is used for the treatment of seasonal allergic rhinitis. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, and group purchasing organizations; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hatfield, the United Kingdom.